Diabetes

Wilmington, NC

107 Diabetes Trials near Wilmington, NC

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CagriSema for Type 2 Diabetes

Wilmington, North Carolina
This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2734 Participants Needed

This trial is testing finerenone, a drug that helps protect kidneys and hearts, in people with chronic kidney disease and type 1 diabetes. The study aims to see how well finerenone works in slowing down kidney damage. Researchers will also monitor the safety of the drug by tracking any medical issues participants experience. Finerenone has been shown to delay the progression of chronic kidney disease and reduce cardiovascular events in patients with diabetic kidney disease, particularly type 2 diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

220 Participants Needed

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

13299 Participants Needed

The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

150 Participants Needed

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:10 - 17

165 Participants Needed

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14012 Participants Needed

CT-388 for Type 2 Diabetes and Obesity

Wilmington, North Carolina
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

360 Participants Needed

AZD5004 for Type 2 Diabetes

Wilmington, North Carolina
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

406 Participants Needed

ALN-KHK for Type 2 Diabetes

Wilmington, North Carolina
This trial is testing a new drug called ALN-KHK to see how safe it is and how the body processes it. They are also testing another drug called KHK to check its safety and effectiveness. The study targets patients who might benefit from these drugs, aiming to understand their safety and how they work in the body.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

49 Participants Needed

NNC0519-0130 for Type 2 Diabetes

Wilmington, North Carolina
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

288 Participants Needed

DMR for Type 2 Diabetes

Wilmington, North Carolina
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.

Trial Details

Trial Status:Recruiting
Age:21 - 70

320 Participants Needed

BI 456906 for Diabetes and Obesity

Wilmington, North Carolina
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

756 Participants Needed

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

125 Participants Needed

Retatrutide for Type 2 Diabetes

Wilmington, North Carolina
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

480 Participants Needed

BMF-219 for Type 1 Diabetes

Wilmington, North Carolina
This trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

37 Participants Needed

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

404 Participants Needed

This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2749 Participants Needed

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

999 Participants Needed

Retatrutide for Obesity

Wilmington, North Carolina
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

10000 Participants Needed

This trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

618 Participants Needed

Why Other Patients Applied

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

YN
Diabetes PatientAge: 35

"I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

IJ
Diabetes PatientAge: 25

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67
This trial is testing retatrutide, a medication for people with type 2 diabetes who are overweight or obese, including some with sleep apnea. The medication aims to help control blood sugar levels and may also aid in weight loss.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1000 Participants Needed

Maridebart Cafraglutide for Diabetes

Myrtle Beach, South Carolina
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

409 Participants Needed

Tirzepatide for Type 2 Diabetes

Morehead City, North Carolina
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

780 Participants Needed

This trial tests if combining finerenone and empagliflozin can better slow down kidney damage in patients with CKD and T2D compared to using each drug alone. Finerenone protects kidneys, while empagliflozin lowers blood sugar. Empagliflozin has shown significant improvements in glycemic control, body weight, and blood pressure, and finerenone has demonstrated improved outcomes in patients with chronic kidney disease and type 2 diabetes. The study will measure protein levels in urine to assess effectiveness.

Trial Details

Trial Status:Active Not Recruiting

1664 Participants Needed

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1576 Participants Needed

Orforglipron for Type 2 Diabetes

New Bern, North Carolina
This trial is testing a new medication called orforglipron to help adults with type 2 diabetes who can't control their blood sugar with diet and exercise alone. The medication aims to improve how the body manages sugar levels.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

520 Participants Needed

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

568 Participants Needed

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1000 Participants Needed

This trial is testing HTD1801, a medication, to see if it can help adults with NASH and liver fibrosis who also have type 2 diabetes or pre-diabetes. The goal is to see if the medication can reduce liver inflammation and scarring, thereby improving liver health.

Trial Details

Trial Status:Completed
Trial Phase:Phase 2

218 Participants Needed

This trial is testing AMG 133, a new drug, to see if it helps people lose weight and keep it off. It targets overweight or obese individuals, both with and without Type 2 diabetes. The drug may work by affecting metabolism or appetite.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

592 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Diabetes clinical trials in Wilmington, NC pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Diabetes clinical trials in Wilmington, NC work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Wilmington, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Wilmington, NC for Diabetes is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Wilmington, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Diabetes medical study in Wilmington, NC?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Diabetes clinical trials in Wilmington, NC?

Most recently, we added GNTI-122 for Type 1 Diabetes, Management Program for Chronic Kidney Disease in Type 2 Diabetes and Screening Program for Chronic Kidney Disease in Type 2 Diabetes to the Power online platform.

What is the best treatment for diabetes?

There isn’t one “best” therapy—think of diabetes care as two layers. First, everyone benefits from diabetes education, a balanced diet, regular activity, and routine monitoring. Second, medicines are chosen by diabetes type and other health issues: type 1 always needs insulin (preferably with a continuous glucose monitor or hybrid pump), while type 2 usually starts with metformin plus lifestyle changes and, if more help is needed, adds a GLP-1 or SGLT2 drug (especially when heart, kidney, or weight problems exist) before considering insulin. Work with your healthcare team to revisit these steps every few months so treatment keeps pace with your goals and any new health changes.

How much weight do you need to lose to reverse type 2 diabetes?

Most studies find that you need to shed about 10–15 % of your starting weight—roughly 15 kg (33 lb) for an average-sized adult—to give yourself the best shot at putting type-2 diabetes into remission (normal sugars without diabetes pills). The closer you are to diagnosis and the more weight you keep off—especially if you can pass the 15 kg mark—the higher the odds (up to 80 % in some trials), while smaller losses still improve blood sugar but rarely achieve full remission. Work with your healthcare team to choose a safe approach (intensive diet program, GLP-1 medications, or bariatric surgery) and to monitor that blood-sugar targets stay on track once the weight comes off.

Can diabetics still get Ozempic?

Yes—if you have type-2 diabetes and meet NICE criteria (poor glucose control despite other drugs, or need for weight loss/heart-protection), your GP or diabetes nurse can still prescribe Ozempic; it is not used for type-1 diabetes, pregnancy, or in children. The practical hurdle is the current UK supply shortage, so existing users should order repeats early and stay in touch with their pharmacist, while new patients may need to start a similar medicine (e.g., dulaglutide) until stock returns.

When will oral insulin be available?

No insulin pill has been approved yet. The most advanced candidates (such as insulin tregopil and ORMD-0801) are still redesigning or preparing large Phase 3 studies, and newer “chocolate-capsule” nano-formulations have not even begun human trials until at least 2025. If upcoming studies succeed, regulatory review and manufacturing mean that everyday prescription use is unlikely before the late-2020s at the earliest.

Why is type 2 diabetes not curable?

Type 2 diabetes isn’t considered curable because its root problems—body-wide insulin resistance and gradual loss of insulin-producing β-cells—can return whenever weight or lifestyle slips, and adult β-cells don’t fully regrow once lost. Big, sustained weight loss (through diet, bariatric surgery, or powerful medications) can put the disease into remission for years, but the underlying susceptibility remains, which is why regular follow-up and healthy habits must continue even when blood sugar is normal.

Can I stop taking metformin when my sugar is back to normal?

Normal readings don’t necessarily mean diabetes is cured; for many people the numbers stay normal only because metformin is on board, and stopping it without a plan can let sugars creep back up. Talk with your clinician about whether you truly meet “remission” criteria (HbA1c < 6.5 % for at least 6 months, stable weight, good kidney function); if so, you can try a monitored dose-reduction, check home glucose and repeat labs in 3 months, and restart the drug promptly if levels rise. In short, never quit metformin on your own—make it a shared, step-by-step decision that includes a taper and clear follow-up.

Can a person fully recover from diabetes?

Type 1 diabetes cannot presently be cured; people need lifelong insulin. In type 2 diabetes, some individuals—especially soon after diagnosis—can achieve remission (normal blood-sugar readings without diabetes medicines) through substantial, sustained weight loss or bariatric surgery, but the underlying tendency can return, so regular check-ups remain essential. So while you may control or even “switch off” type 2 diabetes for a time, no form of diabetes is considered permanently gone.

Which country has the cure for diabetes?

No country has an approved, take-home “cure” for diabetes; the Chinese cell-therapy result you may have seen was a one-patient, early-stage experiment that still needs larger trials and regulatory review. Worldwide teams—from China to the United States, Canada, Europe and beyond—are testing stem-cell implants, gene editing and immune therapies, but for now the proven way to stay healthy is tight glucose monitoring, modern medications (e.g., metformin, GLP-1 or insulin) and lifestyle changes, with bariatric surgery offering remission for some people with type 2 diabetes. Stay alert for peer-reviewed trial results and discuss any experimental option with your diabetes specialist before pursuing treatment abroad.

What is the record trial for diabetes?

RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) was a 5-year study of 4,458 adults with type 2 diabetes that compared adding rosiglitazone to metformin or a sulfonylurea versus the standard metformin-plus-sulfonylurea combination. It showed no overall difference in cardiovascular deaths or hospitalisations (hazard ratio 0.99), but rosiglitazone roughly doubled the risk of heart-failure events and increased bone fractures; these safety concerns, rather than glucose control, ultimately led regulators and doctors to curb use of the drug.

What is the A1C goal for a 70 year old?

For a 70-year-old who already has diabetes, guidelines use a sliding scale: aim below about 7–7.5 % if the person is otherwise healthy and independent, below 8 % if they have multiple illnesses or mild functional decline, and up to 8.5 % if they are frail or in long-term care—these higher limits reduce the risk of dangerous low-blood-sugar episodes. If the 70-year-old is only being screened, the usual cut-offs still apply (normal < 5.7 %, pre-diabetes 5.7-6.4 %, diabetes ≥ 6.5 % confirmed). Work with the healthcare team to choose the target that balances day-to-day safety with long-term benefit.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security